Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) rose nearly 3% towards the end of trading, with a current increase of 2.04%, priced at HKD 7.51, and a trading volume of HKD 408 million [1] Group 1: Clinical Application Approval - CSPC Pharmaceutical's wholly-owned subsidiary, CSPC Ouyi Pharmaceutical Co., Ltd., has had its clinical application for Beipaidu Acid Tablets accepted by the China National Medical Products Administration (NMPA) [1] - Beipaidu Acid is an ATP-citrate lyase inhibitor used to lower low-density lipoprotein cholesterol (LDL-C) in adult patients who cannot tolerate statin therapy, reducing the risk of myocardial infarction and coronary artery revascularization [1] Group 2: Market Potential - Beipaidu Acid was first approved by the FDA in the United States in 2020, and market analysts estimate that it could capture up to 25% of the cholesterol medication market, with peak sales expected to reach between USD 2 billion to USD 3 billion [1] - Currently, no original or generic versions of Beipaidu Acid Tablets have been launched in the domestic market, with four companies, including CSPC Ouyi Pharmaceutical, having their clinical applications accepted, indicating the start of a first-to-market competition [1]

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) rose nearly 3% towards the end of trading, currently up 2.04% at HKD 7.51, with a trading volume of HKD 408 million [1] Group 1: Clinical Application Approval - CSPC Pharmaceutical's wholly-owned subsidiary, CSPC Ouyi Pharmaceutical Co., Ltd., has received acceptance for the clinical application of Beipiduo Acid Tablets, classified as a Class 3 chemical drug by the China National Medical Products Administration (NMPA) [1] - Beipiduo Acid is an ATP-citrate lyase inhibitor primarily used to lower low-density lipoprotein cholesterol (LDL-C) in adult patients who cannot tolerate statin therapy, reducing the risk of myocardial infarction and coronary artery revascularization [1] Group 2: Market Potential - Beipiduo Acid was first approved for marketing by the FDA in the United States in 2020, and market analysts estimate that it could capture up to 25% of the cholesterol medication market, with peak sales expected to reach between USD 2 billion to USD 3 billion [1] - Currently, no original or generic versions of Beipiduo Acid have been launched in the domestic market, but four companies, including CSPC Ouyi Pharmaceutical, have had their clinical applications accepted, indicating the start of a competition for the first generic version [1]

大摩已更新石药集团的风险回报评估，并纳入第三季度业绩，分别下调集团2025年至2026年销售额预测 分别1%及2%，2027年销售额预测维持不变。营运费用亦根据管理层指引及观察到的趋势进行了修正。 因此，同期经常性净利润预估下调4%、下调4%和维持不变。 摩根士丹利发布研报称，目前预测石药集团(01093)2026年销售额及经常性净利润将增长分别为5%、 7%;随着新产品上市获市场认可，增长在2027年分别加速至6%、10%。此外，大摩已保守地将集团终端 增长率从4%下调至3.5%，由此得出之现金流量折现法的目标价为10.4港元(原本11港元);评级增持。 ...

智通财经APP获悉，摩根士丹利发布研报称，目前预测石药集团(01093)2026年销售额及经常性净利润将 增长分别为5%、7%;随着新产品上市获市场认可，增长在2027年分别加速至6%、10%。此外，大摩已 保守地将集团终端增长率从4%下调至3.5%，由此得出之现金流量折现法的目标价为10.4港元(原本11港 元);评级增持。 大摩已更新石药集团的风险回报评估，并纳入第三季度业绩，分别下调集团2025年至2026年销售额预测 分别1%及2%，2027年销售额预测维持不变。营运费用亦根据管理层指引及观察到的趋势进行了修正。 因此，同期经常性净利润预估下调4%、下调4%和维持不变。 ...

大摩目前预测，集团2026年销售额及经常性净利润将增长分别为5%、7%；随着新产品上市获市场认 可，增长在2027年分别加速至6%、10%。此外，大摩已保守地将集团终端增长率从4%下调至3.5%，由 此得出之现金流量折现法的目标价从11港元下调至10.4港元，评级"增持"。 摩根士丹利发表研报指，已更新石药集团的风险回报评估，并纳入第三季度业绩，分别下调集团2025年 至2026年销售额预测分别1%及2%，2027年销售额预测维持不变。营运费用亦根据管理层指引及观察到 的趋势进行了修正。因此，同期经常性净利润预估下调4%、下调4%和维持不变。 ...

Core Viewpoint - The Hong Kong innovation drug sector is experiencing a correction, leading to increased capital inflow into core assets, particularly the Hong Kong Stock Connect Innovation Drug ETF (520880), which has seen a significant increase in fund subscriptions despite a market downturn [1][6]. Group 1: Market Performance - The Hong Kong Stock Connect Innovation Drug ETF (520880) has experienced a decline of over 22% since early September, reaching a five-month low as of December 16 [1][6]. - Despite the price drop, the ETF has seen a net subscription for seven consecutive days, with the total fund shares rising to 4.172 billion, marking a new high since its inception [1][6]. Group 2: Market Analysis - The overall pressure on the Hong Kong market in December has made high-growth sectors like innovation drugs more susceptible to capital outflows [3][8]. - Expectations of a potential interest rate hike by the Bank of Japan and a tightening of external liquidity are contributing to increased volatility in the sector [3][8]. - Year-end risk aversion and profit-taking by institutional investors are also influencing market dynamics [3][8]. Group 3: Investment Logic - The underlying drivers for the growth of China's innovation drug sector, including accelerated international expansion, technological upgrades, and commercialization, remain intact [3][8]. - Upcoming industry events, such as clinical data progress and significant business development transactions, are expected to provide positive catalysts for the sector, with a focus on the first quarter of 2026 [3][8]. Group 4: ETF Characteristics - The Hong Kong Stock Connect Innovation Drug ETF (520880) is characterized by three unique advantages: it exclusively covers innovation drug companies, has a high concentration of leading firms with over 72% weight in the top ten stocks, and employs measures to control risks associated with less liquid components [3][9]. - As of November 30, the ETF's scale was 2.142 billion, with an average daily trading volume of 458 million, making it the largest and most liquid ETF tracking the same index [4][11].

Core Viewpoint - The "Precision Radiotherapy for Depression" project aims to advance clinical research and application breakthroughs in treating depression using new generation precision radiotherapy technology, specifically the ZAP-X system, which is currently in the clinical research phase focusing on safety and efficacy [1] Group 1: Market Overview - Depression is one of the most common mental disorders globally, with approximately 332 million people affected, including over 90 million in China, of which 10 to 12 million require treatment during depressive episodes [1] - The antidepressant market in China is highly competitive, with SSRIs and SNRIs accounting for about 60% of the market share. The sales revenue for antidepressants in sample hospitals is expected to exceed 8 billion yuan in 2024, with SSRIs contributing 3.58 billion yuan (43.44%) and SNRIs 1.42 billion yuan (17.18%) [3][4] - The global antidepressant market was valued at approximately $14.5 billion in 2022 and is projected to reach $17.6 billion by 2030, with China's market expected to grow to 23.8 billion yuan by 2030, reflecting a compound annual growth rate (CAGR) of 4.2% from 2022 to 2030 [3][4] Group 2: Innovation and Development - There is a significant unmet clinical need as about 30% of patients do not respond to existing antidepressants, highlighting the potential of neuromodulation technologies as a complementary treatment, especially for treatment-resistant depression (TRD) [6] - Non-invasive neuromodulation techniques, such as transcranial magnetic stimulation (TMS), are gaining traction in clinical settings. TMS has been FDA-approved for depression treatment since 2008, and several certified TMS systems are available globally [7] - The "Precision Radiotherapy for Depression" project focuses on exploring the clinical efficacy and safety of low-dose radiotherapy for treatment-resistant depression, aiming to establish a new neuromodulation method with high precision targeting [9][10] Group 3: Research and Clinical Trials - The project is part of a broader trend in the development of innovative antidepressant therapies, with numerous new drugs in clinical trials targeting various mechanisms [4][5] - The project aims to investigate the potential of radiotherapy as a neuromodulation method, traditionally used for brain tumors, to treat depression, with initial studies showing promising results [10] - Collaboration among various professionals and addressing regulatory, funding, and resource challenges are crucial for the project's success and eventual commercialization [11]

来源：新浪基金 今日（12月16日）A股三大指数集体回调，沪指跌逾1%，创业板指跌超2%，全市场超4300只个股下 跌，仅千余只个股收涨，沪深两市成交额1.72万亿元，较昨日小幅缩量。 为何市场深度回调？发生了什么？从全球的角度来看，最大的变数可能是日本央行加息箭在弦上，利率 料升至30年新高！日本央行12月18日-19日将召开金融政策决定会议，最可能的方案是加息0.25%至 0.75%，达到1995年以后30年来的最高利率水平。 ①重仓互联网龙头的——港股互联网ETF（513770）近8日狂揽8.26亿元； ②100%创新药研发标的——港股通创新药ETF（520880）近6日连续吸金超2亿元； ③自带"科技+红利"哑铃策略的——香港大盘30ETF（520560）近9日连续获资金净流入，合计金额7089 万元； ④全市场首只聚焦"港股芯片"产业链的——港股信息技术ETF（159131）继昨日资金净流入639万元， 今日盘中再获实时净申购500万份。 盘面上港股市场持续走弱的表现，可能与日元套息交易走弱存在一定关系。多数人士认为，日本央行加 息不会对当下的市场造成太大的冲击。虽然日本央行可能出售 ETF，但套息 ...

Market Overview - The A-share market experienced a collective pullback, with the Shanghai Composite Index dropping over 1% and the ChiNext Index falling more than 2%, as over 4,300 stocks declined while only about 1,000 stocks rose [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.72 trillion yuan, slightly lower than the previous day [1] Global Influences - The potential interest rate hike by the Bank of Japan is a significant factor, with expectations of an increase of 0.25% to 0.75%, reaching the highest level in 30 years [1] - The weakening of the Hong Kong stock market may be related to the decline in yen carry trades, although many believe the impact of the Bank of Japan's rate hike will be limited [1] Fund Flows - There is a notable inflow of capital into quality Hong Kong stocks, with several ETFs attracting significant investments: - The Hong Kong Internet ETF (513770) has seen inflows of 826 million yuan over the past eight days [1] - The Hong Kong Innovation Drug ETF (520880) has attracted over 200 million yuan in six days [1] - The Hong Kong Large Cap 30 ETF (520560) has received a total of 70.89 million yuan in net inflows over nine days [1] - The Hong Kong Information Technology ETF (159131) has also seen net inflows [1] Sector Focus - The Hong Kong Medical ETF (159137) is currently being launched, focusing on 48 leading companies in the medical sector, with 39 being exclusive to the Hong Kong market [3] - The market is viewed as being at a strategic opportunity point, with valuations at a global low and strong capital inflows, suggesting limited downside and significant upside potential for long-term investors [3] Digital Currency and Financial Technology - The promotion of digital RMB smart contracts is enhancing consumption policies, with the largest financial technology ETF (159851) rising against the market trend, gaining 0.75% [5][6] - The financial technology sector is expected to see increased activity due to regulatory changes that encourage insurance companies to invest more in A-shares [8] Innovation Drug Sector - The Hong Kong Innovation Drug ETF (520880) has been under pressure, reaching a new low, with 29 out of 37 covered companies declining [10] - Despite the downturn, there is a significant net inflow into the ETF, indicating a potential buying opportunity as the sector adjusts [11][13] AI and Internet Sector - The Hong Kong Internet ETF (513770) has experienced a decline of 21% from its yearly high, but remains attractive for long-term investment due to its relatively low valuation compared to other indices [21] - The ETF has seen continuous inflows, indicating strong buying interest despite recent market volatility [18][23]

Core Viewpoint - The Hong Kong Stock Connect innovative drug ETF (520880) is experiencing a significant decline, reaching a new low in nearly five months, with a drop of 1.91% and nearing its initial listing price level. The underlying 37 innovative drug companies saw 29 decline and 8 rise, indicating a challenging market environment for the sector [1][9]. Market Performance - In December, the Hong Kong Stock Connect innovative drug ETF (520880) has only recorded two days of gains over 12 trading days, reflecting a broader market pressure. The innovative drug sector, characterized by high valuation elasticity, is particularly vulnerable to capital outflows [10]. - The ETF has seen a significant adjustment, with a drop of over 22% since early September, indicating a substantial correction that may have released some elastic space for future recovery [4][12]. Fund Flows - Recent market adjustments have prompted noticeable buying activity, with over 75 million yuan net subscriptions in a single day, leading to a total of over 200 million yuan in net inflows over six consecutive days. The ETF's share has risen to a new high of 4.148 billion shares [2][12]. Technical Analysis - The technical indicators for the Hong Kong Stock Connect innovative drug ETF (520880) suggest a bearish trend, with the MACD showing a clear downtrend. The DIF is below the DEA, indicating strong downward momentum in the short term [5][12]. Long-term Outlook - The fundamental drivers for the development of China's innovative drug sector, including accelerated international expansion, technological upgrades, and commercialization, remain unchanged. Upcoming industry events and breakthroughs are expected to provide positive catalysts, with a focus on the first quarter of 2026 [14]. ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) is noted for its unique advantages, including a pure focus on innovative drugs without CXO companies, a significant concentration of leading firms with over 72% weight in the top ten holdings, and controlled risks through forced de-weighting of less liquid stocks [15][16][17].